


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

What is claimed is:

1. A compound of the formula (I) and/or a pharmaceutically acceptable salt and/or solvate thereof,



wherein,

R¹ is methyl, ethyl or hydroxymethyl;

R² is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C₁-C₅-alkoxy, hydroxy-C₂-C₄-alkoxy or C₁-C₂-alkoxy-C₂-C₄-alkoxy for the para position,

or

pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C₁-C₅-alkoxy, hydroxy-C₂-C₄-alkoxy or C₁-C₂-alkoxy-C₂-C₄-alkoxy for the para position,


or

a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F;

and

R³ is H or methyl.

2. A compound according to claim 1, of formula (Ib)



3. A compound according to claim 1 or claim 2, wherein
R² is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C₁-C₅-alkoxy, hydroxy-C₂-C₄-alkoxy or C₁-C₂-alkoxy-C₂-C₄-alkoxy for the para position.
4. A compound according to claim 1 or claim 2, wherein
R² is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C₁-C₅-alkoxy, hydroxy-C₂-C₄-alkoxy or C₁-C₂-alkoxy-C₂-C₄-alkoxy for the para position.
5. A compound according to claim 1 or claim 2, wherein
R² is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
6. A compound according to any one of claims 1 to 5, wherein
R¹ is methyl.
7. A compound according to any one of claims 1 to 5, wherein
R¹ is ethyl.
8. A compound according to any one of claims 1 to 5, wherein
R¹ is hydroxymethyl.

9. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, selected from

(4S,5R)-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-5-thiazol-2-yl-oxazolidin-2-one,

(4S*,5S*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5-(4-methoxyphenyl)oxazolidin-2-one,

(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydroxymethyl)-5-(4-methoxyphenyl)oxazolidin-2-one,

(4S*,5R*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5-phenyloxazolidin-2-one,

(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-methyl-5-phenyloxazolidin-2-one,

(4R*,5R*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5-(3-methoxyphenyl)oxazolidin-2-one,

(4S,5R)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5-(thiazol-2-yl)oxazolidin-2-one,

3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-ethyl-5-pyridin-3-yl-oxazolidin-2-one,

3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-5-pyridin-3-yl-oxazolidin-2-one,

(4S,5S)-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-hydroxymethyl-5-phenyl-oxazolidin-2-one,

(4S,5S)-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-5-thiazol-2-yl-oxazolidin-2-one,

(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydroxymethyl)-5-(4-(2-methoxyethoxy)phenyl)oxazolidin-2-one,

(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-5-(4-(2-hydroxyethoxy)phenyl)-4-(hydroxymethyl)oxazolidin-2-one or

(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydroxymethyl)-5-(4-(3-hydroxypropoxy)phenyl)oxazolidin-2-one.

10. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, which is

(4S,5R)-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-5-thiazol-2-yl-oxazolidin-2-one.

~~1011.~~ A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 910, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

~~1112.~~ A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 910, or a pharmaceutically acceptable salt thereof, and one or more therapeutically active co-agents.

~~12.~~ A method of treating a subject comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9.

~~13.~~ A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use as a medicament.

~~1413.~~ A compound according to any one of claims 1 to 910, or a pharmaceutically acceptable salt thereof, for use in the treatment of non-melanoma skin cancers, selected from basal cell carcinoma and squamous cell carcinoma, pre-malignant stages of non-melanoma skin cancers or other hyperproliferative skin disorders caused by dysregulation of skin fibroblasts.

14. A compound for use according to claim 13, wherein the non-melanoma skin cancer is squamous cell carcinoma, the pre-malignant stage of non-melanoma skin cancer is actinic keratosis and the hyperproliferative skin disorder caused by dysregulation of skin fibroblasts is keloids.

15. Use of a compound according to any one of claims 1 to 910, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of non-melanoma skin cancers, selected from basal cell carcinoma and squamous cell carcinoma, pre-malignant stages of non-melanoma skin cancers or other hyperproliferative skin disorders caused by dysregulation of skin fibroblasts.

16. Use according to claim 15, wherein the non-melanoma skin cancer is squamous cell carcinoma, the pre-malignant stage of non-melanoma skin cancer is actinic keratosis and the hyperproliferative skin disorder caused by dysregulation of skin fibroblasts is keloids.